<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603861</url>
  </required_header>
  <id_info>
    <org_study_id>15511</org_study_id>
    <secondary_id>I7S-EW-HBEB</secondary_id>
    <nct_id>NCT02603861</nct_id>
  </id_info>
  <brief_title>A Study of LY3154207 on Sleep in Healthy Male Participants</brief_title>
  <official_title>An Evaluation of the Impact of Single Doses of LY3154207 on Sleep Latency in Sleep-Deprived Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of single doses of LY3154207 on the amount of time it
      takes for healthy sleep-deprived men to fall asleep. The study will also estimate how much
      LY3154207 gets into the blood stream and how long it takes the body to remove it. Information
      about any side effects that occur will be collected. Each participant will complete four
      study periods, which will last a total of about 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Sleep Onset</measure>
    <time_frame>Day 1: 2 hours post dose through 8 hours post dose in each period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of LY3154207</measure>
    <time_frame>Day 1: 1 hour post dose through 24 hours post dose in each period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve (AUC) of LY3154207</measure>
    <time_frame>Day 1: 1 hour post dose through 24 hours post dose in each period.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching LY3154207 administered once orally in one of four periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally in no more than one of the four periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally in no more than one of the four periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 - Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered orally in no more than one of the four periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg modafinil administered orally in no more than one of the four periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3154207</intervention_name>
    <description>LY3154207 administered orally.</description>
    <arm_group_label>LY3154207 - Dose 1</arm_group_label>
    <arm_group_label>LY3154207 - Dose 2</arm_group_label>
    <arm_group_label>LY3154207 - Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>Modafinil administered orally.</description>
    <arm_group_label>Modafinil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males 18 years of age or older who have given consent and are reliable
             and willing to make themselves available for the duration of the study and are willing
             to follow study procedures

          -  Have a regular sleep pattern with routine time spent in bed between 6.5 hours and 9
             hours each night

        Exclusion Criteria:

          -  Are shift workers who shifted work within 14 days prior to screening or plan to during
             the study

          -  Have a known sleep disorder or history of a sleep disorder

          -  Have traveled 2 time zones or more within 7 days prior to screening or plan to during
             the study

          -  Regularly take naps during the day

          -  Are hearing impaired
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Unit at Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

